Regeneron Pharmaceuticals Inc. has been in the spotlight for its varied activities and performance. Financial analyst, Jim Cramer, praised the company's oncology portfolio. Multiple firms, including Ieq Capital LLC and Intech Investment Management LLC, recently increased their stock holdings in the company. Regeneron reported strong quarterly results due to the robust demand for its eczema and eye treatments. However, the company is facing a lawsuit against its directors. There have been several insider trading activities with director Arthur Ryan selling shares. The company is looking to revolutionize healthcare by integrating genomics technology into its operations. There's a bullish trend on the street towards Regeneron, with stock potentially undervalued by up to 47%. Despite some setbacks, such as FDA declining to approve Regeneron's blood cancer therapy, and a DOJ complaint regarding drug-price manipulation, the company has shown resilience. Their stock performance has persistently outpaced the growth in underlying earnings. Recently, Regeneron collaborated with Mammoth, a Doudna-established company, to explore gene-editing therapies, and it's push on experimental gene therapy shows significant promise.
Regeneron Pharmaceuticals REGN News Analytics from Mon, 08 Jan 2024 08:00:00 GMT to Sat, 21 Sep 2024 10:02:04 GMT -
Rating 2
- Innovation 5
- Rumor 4
